| Literature DB >> 35625924 |
Aprill Kee Oliva1,2, Meriem Bejaoui1,2,3, Atsushi Hirano4, Takashi Arimura3, Tran Ngoc Linh3, Eriko Uchiage3, Sachiko Nukaga4, Kenichi Tominaga3, Hiroyuki Nozaki4, Hiroko Isoda1,2,3,5.
Abstract
A person's quality of life can be adversely affected by hair loss. Microalgae are widely recognized for their abundance and rich functional components. Here, we evaluated the hair growth effect of a green alga, Botryococcus terribilis (B. terribilis), in vitro using hair follicle dermal papilla cells (HFDPCs). We isolated two types of cells from B. terribilis-green and orange cells, obtained from two different culture conditions. Microarray and real time-PCR results revealed that both cell types stimulated the expression of several pathways and genes associated with different aspect of the hair follicle cycle. Additionally, we demonstrated B. terribilis' effect on collagen and keratin synthesis and inflammation reduction. We successfully isolated a novel compound, methylated-meijicoccene (me-meijicoccene), and C32 botryococcene from B. terribilis to validate their promising effects. Our study revealed that treatment with the two compounds had no cytotoxic effect on HFDPCs and significantly enhanced the gene expression levels of hair growth markers at low concentrations. Our study provides the first evidence of the underlying hair growth promoting effect of B. terribilis and its novel compound, me-meijicoccene, and C32 botryococcene.Entities:
Keywords: Botryococcus terribilis; C32 botryococcene; dermal papilla cells; hair growth; me-meijicoccene
Year: 2022 PMID: 35625924 PMCID: PMC9138970 DOI: 10.3390/biomedicines10051186
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1Distribution of fold changes of DEGs. (A) A volcano plot displaying the DEGs regulated between BT-GC and control. (B) A volcano plot displaying the DEGs regulated between BT-OC and control. These volcano plots were generated using Transcriptome Analysis Console 4 software. The red dots represent the upregulated genes whereas the green dots pertain to the downregulated genes. The gray dots are the unregulated genes. These DEGs are under the criteria of fold change >1.5 and <−1.5. (C) Distribution of DEGs regulated by BT-GC and (D) distribution of DEGs regulated by BT-OC. (E) Venn diagram showing the upregulated genes of BT-GC and BT-OC and the number of overlaps. (F) Venn diagram showing the downregulated genes of BT-GC and BT-OC and the number of overlapping genes.
Figure 2Significantly enriched biological processes of BT-GC and BT-OC DEGs. (A) Summary of the top significantly enriched gene ontologies (GO) by the upregulated DEGs of BT-GC. (B) The most significantly enriched GOs by the downregulated DEGs of BT-GC. (C) Summary of the most significantly enriched GOs by the upregulated DEGs of BT-OC. (D) The most significantly enriched GOs by the downregulated DEGs of BT-OC. Analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery ver.6.8 (DAVID). * Statistically significant (p-value ≤ 0.05), ** statistically significant (p-value ≤ 0.01), *** statistically significant (p-value ≤ 0.001).
Figure 3Significantly enriched KEGG pathways of BT-GC and BT-OC DEGs. (A) Bubble plot of the most significantly enriched KEGG pathways by the upregulated DEGs of BT-GC. (B) The most significantly enriched KEGG pathways by the downregulated DEGs of BT-GC. (C) Bubble plot of the most significantly enriched KEGG pathways by the upregulated DEGs of BT-OC. (D) The most significantly enriched KEGG pathways by the downregulated DEGs of BT-OC. The x-axis displays the fold enrichment, the y-axis represents the enriched pathways, the size of the bubbles pertains to the count/number of genes within the pathway, and the colors refer to the significance (p-value ≤ 0.05). The analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery ver.6.8 (DAVID). Visualization was conducted using R programming.
Summary of the top upregulated hair growth-associated genes by BT-GC.
| Gene Symbol | Gene Name | Biological Function | Fold-Change | * |
|---|---|---|---|---|
|
| Corin, Serine Peptidase | Morphogenesis of HF | 33.29 | 4.37 × 10−20 |
|
| SRY (sex determining region Y) box 2 | Controls mesenchymal–epithelial crosstalk | 5.31 | 1.72 × 10−17 |
|
| Signal transducer and activator of transcription 5 | Anagen inducer | 4.2 | 1.25 × 10−14 |
|
| Wntless | Wnt secretion and pathway | 3.83 | 1.19 × 10−13 |
|
| Fibroblast growth factor 7 | HF morphogenesis; hair growth cycle regulation | 3.81 | 1.09 × 10−16 |
|
| Catenin (cadherin associated protein) beta 1 | Regulation of anagen phase regulation, fibroblast growth, cell proliferation, and HF morphogenesis | 3.59 | 1.09 × 10−14 |
|
| Microphthalmia-associated transcription factor | Controls pigmentation enzymes | 2.89 | 5.36 × 10−12 |
|
| Alkaline phosphatase | Wnt/β-catenin pathway regulator | 2.39 | 6.93 × 10−13 |
|
| Wingless-type MMTV, member 11 | Wnt pathway | 2.36 | 5.19 × 10−14 |
|
| Collagen, type III, alpha 1 | Fibrillogenesis in the skin and the HF | 2.36 | 1.85 × 10−14 |
|
| Insulin-like growth factor Binding Protein 2 | IGF1 receptor | 2.17 | 1.31 × 10−13 |
|
| Versican | Cell aggregation, adhesion, sand proliferation | 2.1 | 3.03 × 10−13 |
|
| SRY (sex determining region Y)-box 4 | Hair regeneration | 2.08 | 4.08 × 10−12 |
|
| Bone morphogenetic protein 8a | Control HF growth and development | 1.98 | 6.30 × 10−12 |
|
| Signal transducer and activator of transcription 3 | Wound healing and HF development | 1.9 | 4.92 × 10−12 |
|
| Fibroblast growth factor 22 | Cutaneous development and repair | 1.82 | 4.59 × 10−11 |
|
| Recombinant signal binding protein J | Transcriptional effector of Notch pathway | 1.74 | 3.51 × 10−09 |
|
| Insulin-like growth factor 1 | Maintains anagen phase and cell proliferation | 1.7 | 1.09 × 10−08 |
|
| Lymphoid enhancer factor 1 | Regulation of DPCs proliferation by Wnt signaling | 1.58 | 1.44 × 10−09 |
|
| Hepatocyte growth factor | Promotes follicular growth | 1.57 | 1.38 × 10−08 |
|
| Fibroblast growth factor 1 | Anagen inducer | 1.53 | 7.67 × 10−07 |
|
| Fibroblast growth factor receptor 1 | Primary transducers of FGF signaling in DP | 1.53 | 1.82 × 10−08 |
* ANOVA was performed to assess the level of significance between groups. The gene expression was considered significant when the fold change was ≥1.5-fold (BT-GC versus control).
Summary of the top upregulated hair growth-associated genes by BT-OC.
| Gene Symbol | Gene Name | Biological Function | Fold-Change | * |
|---|---|---|---|---|
|
| Versican | Regulates Cell aggregation, adhesion, and proliferation | 5.46 | 5.66 × 10−18 |
|
| Corin, Serine Peptidase | Morphogenesis of HF | 22.08 | 1.84 × 10−19 |
|
| Catenin (cadherin associated protein), beta 1 | Regulation of anagen phase regulation, fibroblast growth, cell proliferation, and HF morphogenesis | 4.41 | 2.04 × 10−15 |
|
| Fibroblast growth factor 7 | HF morphogenesis; hair growth cycle regulation | 4.09 | 6.16 × 10−17 |
|
| Wntless | Wnt secretion and pathway | 3.89 | 1.06 × 10−15 |
|
| Collagen, type III, alpha 1 | Fibrillogenesis in the skin and the HF | 3.75 | 1.43 × 10−16 |
|
| Recombinant signal binding protein J | Transcriptional effector of Notch pathway | 3.69 | 1.20 × 10−13 |
|
| Wingless-type MMTV, member 11 | Wnt pathway | 3.14 | 1.39 × 10−16 |
|
| SRY (sex determining region Y) box 2 | Controls mesenchymal-epithelial crosstalk | 2.95 | 2.74 × 10−15 |
|
| Signal transducer and activator of transcription 5 | Anagen inducer | 2.81 | 4.48 × 10−13 |
|
| Insulin-like growth factor 1 | Maintains anagen phase and cell proliferation | 2.51 | 1.41 × 10−13 |
|
| Insulin-like growth factor Binding Protein 2 | IGF1 receptor | 2.44 | 2.73 × 10−14 |
|
| Alkaline phosphatase | Wnt/β-catenin pathway regulator | 2.37 | 7.61 × 10−13 |
|
| Microphthalmia-associated transcription factor | Controls pigmentation enzymes | 2.31 | 5.36 × 10−11 |
|
| Signal transducer and activator of transcription 3 | Wound healing and HF development | 2.09 | 1.01 × 10−12 |
|
| Lymphoid enhancer factor 1 | Regulation of DPCs proliferation by Wnt signaling | 2.06 | 8.88 × 10−12 |
|
| SRY (sex determining region Y)-box 4 | Hair regeneration | 1.97 | 1.86 × 10−13 |
|
| Cadherin 3, Type 1, P-cadherin (placenta) | Cell–cell communication and adhesion | 1.95 | 2.73 × 10−10 |
|
| Fibroblast growth factor 1 | Anagen inducer | 1.94 | 6.17 × 10−11 |
|
| Bone morphogenetic protein 8a | Control HF growth and development | 1.76 | 4.94 × 10−11 |
|
| Fibroblast growth factor 22 | Cutaneous development and repair | 1.63 | 5.04 × 10−10 |
|
| Hepatocyte growth factor | Promotes follicular growth | 1.58 | 2.98 × 10−08 |
|
| Fibroblast growth factor receptor 1 | Primary transducers of FGF signaling in DP | 1.52 | 2.16 × 10−08 |
* ANOVA was performed to assess the level of significance between groups. The gene expression was considered significant when the fold change was ≥1.5-fold (BT-OC versus control).
Summary of the top downregulated hair growth- associated genes by BT-GC.
| Gene Symbol | Gene Name | Biological Function | Fold-Change | * |
|---|---|---|---|---|
|
| Insulin like growth factor binding protein 5 | Negative regulator of cell proliferation in the HF | −13.19 | 1.43 × 10−18 |
|
| Brain-derived Neurotrophic Factor | Catagen induction and inhibition of hair shaft elongation | −3.1 | 2.59 × 10−15 |
|
| Transforming growth factor beta 1 | Catagen induction marker | −2.61 | 2.11 × 10−13 |
|
| Zyxin | Inhibits HF growth by regulating fibroblast HF cycle and promotes cell apoptosis, thus reduced expression enhances hair shaft, delays catagen entry, and HFDPCs proliferation and inductivity | −2.42 | 1.78 × 10−12 |
|
| Dickkopf Wnt signaling pathway inhibitor 3 | Wnt signaling negative regulator | −2.35 | 4.81 × 10−12 |
|
| Bone morphogenetic protein 4 | Suppress proliferation in the hair matrix | −2.31 | 3.11 × 10−10 |
|
| Glycogen synthase kinase 3 beta | Phosphorylation of β-catenin | −1.64 | 1.74 × 10−08 |
|
| AE binding protein 1 | Regulator of telogen HF | −1.59 | 4.84 × 10−11 |
|
| H2A histone family | Stem cell quiescence, Anagen delay | −1.53 | 2.06 × 10−09 |
* ANOVA was performed to assess the level of significance between groups. The gene expression was considered significant when the fold change was ≥1.5-fold (BT-GC versus control).
Summary of the top downregulated hair growth-associated genes by BT-OC.
| Gene Symbol | Gene Name | Biological Function | Fold-Change | * |
|---|---|---|---|---|
|
| Insulin-like growth factor binding protein 5 | Negative regulator of cell proliferation in the hair follicle | −5.29 | 2.63 × 10−13 |
|
| Dickkopf WNT signaling pathway inhibitor 3 | Wnt signaling negative regulator | −3.67 | 2.33 × 10−14 |
|
| Transforming growth factor beta 1 | Catagen induction marker | −2.94 | 5.27 × 10−14 |
|
| Zyxin | Inhibits HF growth by regulating fibroblast HF cycle and promotes cell apoptosis | −2.37 | 5.64 × 10−12 |
|
| Brain-Derived Neurotrophic Factor | Catagen induction and inhibition of hair shaft elongation | −1.94 | 1.26 × 10−13 |
|
| Glycogen synthase kinase 3 beta | Phosphorylation of β-catenin | −1.71 | 3.19 × 10−09 |
|
| LIM Domain Binding 3 | Wnt-responsive gene; Regulation of hair follicle during telogen | −1.53 | 5.35 × 10−06 |
* ANOVA was performed to assess the level of significance between groups. The gene expression was considered significant when fold change was ≥1.5-fold (BT-OC versus control).
Figure 4Enriched molecular functions’ categories by BT-GC and BT-OC and validation by gene expression. (A) Heatmap displaying the relative expression levels of DEGS. This is a comparison between BT-GC, BT-OC, minoxidil, and control. Several biological functions like anti-inflammation, collagen, pigmentation, keratin, and hair growth were chosen to be displayed using this heatmap generated by the online tool Morpheus Broad Institute. Gene expression of (B) CTNNB1, (C) ALPL, (D) FGF1, and (E) RBPJ. There is no significant difference between BT-GC and BT-OC. The result represents the mean ± SD from three independent experiments. An ANOVA test (Tukey’s multiple comparison test) was used to assess the level of significance between the groups. * Statistically significant (p-value ≤ 0.05), ** statistically significant (p-value ≤ 0.01), *** statistically significant (p-value ≤ 0.001), **** statistically significant (p-value ≤ 0.0001), ns (not significant).
Figure 51H-NMR spectra of me-meijicoccene in CDCl3 at 25 °C: (A) whole spectrum; (B,C) partial spectra.
Figure 61H-NMR spectra of C32 botryococcene in CDCl3 at 25 °C: (A) whole spectrum; (B,C) partial spectra.
Figure 7Me-meijicoccene enhanced the gene expression of hair growth-associated markers. (A) Determination of the relative cell viability of HFDPCs after me-meijicoccene treatment for 48 h. Validation of the relative gene expression of (B) CTNNB1, (C) ALPL, (D) FGF1, and (E) RBPJ. Results are expressed using the mean ± SD of three replicates. An ANOVA test (Dunnett’s multiple comparisons test) was used to assess the level of significance between the groups. * Statistically significant (p-value ≤ 0.05), ** statistically significant (p-value ≤ 0.01), *** statistically significant (p-value ≤ 0.001), **** statistically significant (p-value ≤ 0.0001), ns (not significant).
Figure 8C32 botryococcene enhanced the gene expression of hair growth-associated markers. (A) Determination of the relative cell viability of HFDPCs after C32 botryococcene treatment for 48 h. Validation of the relative gene expression of (B) CTNNB1, (C) ALPL, (D) FGF1, and (E) RBPJ. The results are expresses using the mean ± SD of three replicates. An ANOVA test was used to assess the level of significance between the groups. * Statistically significant (p-value ≤ 0.05), ** statistically significant (p-value ≤ 0.01), *** statistically significant (p-value ≤ 0.001), **** statistically significant (p-value ≤ 0.0001), ns (not significant).